FIRST LIGHT DIAGNOSTICS , INC.

Medtech · Acquired

Rapid antimicrobial susceptibility testing platform that identifies pathogens and determines antibiotic susceptibility directly from patient specimens in hours instead of days, using novel MultiPath d

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$3M
Federal grants
$3M
3 awards · 2021–2023
Rank in peer group#84 of 112
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
3
12 pending · first 2023
Rank in peer group#18 of 112

Capital timeline

202120222023FEDERAL ↑EQUITY ↓Cumulative $3M$992K$992K$992K
202120222023FEDERAL ↑EQUITY ↓Cumulative $3M$992K$992K$992K

Latest events

  • Federal grantHealth and Human S · Phase II · Rapid antimicrobial susceptibility testing directly from urine specimens$992K
  • Federal grantHealth and Human S · Phase II · Rapid antimicrobial susceptibility testing directly from urine specimens$992K
  • Federal grantHealth and Human S · Phase II · Rapid antimicrobial susceptibility testing directly from urine specimens$992K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

  • Federal grantsBelow median
  • Granted patents#18 · top 16%
  • Linked publications#22 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 3 granted of 15
  • PendingMethods And Systems For Bacterial AssessmentUSPTOApplication 19371850
  • GrantedDetection And Analysis Of CellsUSPTOUS 12,480,944
  • PendingTest CartridgesUSPTOApplication 18974135
Show all 15 patent records
  • Methods And Systems For Bacterial AssessmentApr 30, 2026 · Application 19371850Pending
  • Detection And Analysis Of CellsNov 25, 2025 · US 12,480,944Granted
  • Test CartridgesNov 20, 2025 · Application 18974135Pending
  • Detection Of TargetsJun 12, 2025 · Application 18743907Pending
  • Test CartridgesApr 29, 2025 · US 12,287,332Granted
  • Microbial Analysis Without Cell PurificationJul 27, 2023 · Application 17282633Pending
  • Kits And Devices For Detecting AnalytesApr 20, 2023 · Application 18082992Pending
  • Kits And Devices For Detecting AnalytesFeb 21, 2023 · US 11,583,853Granted
  • Analysis InstrumentNov 11, 2021 · Application 17282627Pending
  • Systems And Methods For Target Identification And Treatment AnalysisApplication 62741253Pending
  • Test CartridgesApplication PCTUS2019054887Pending
  • Microbial Analysis Without Cell PurificationApplication PCTUS2019054885Pending
  • Analysis InstrumentApplication PCTUS2019054884Pending
  • Detection And Analysis Of CellsApplication PCTUS2019054888Pending
  • Methods And Systems For Bacterial AssessmentApplication 63712857Pending

Recent research by its founders

  • Rapid pathogen identification and phenotypic antimicrobial susceptibility directly from urine specimens202211 cites
  • Rapid Ultrasensitive Detection of <i>Clostridiodes difficile</i> Toxins in Stool Samples Using A Single-Molecule Counting Method20200 cites
  • A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples201820 cites

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .